Clinical trial · Interventional
ORCHARD- Optimising Home Assessment of Rural Patients
Optimising Remote Consulting and Home Assessment of Medically Vulnerable Rural Patients During Unscheduled and Planned Primary Care- Assessing Feasibility of the ORCHARD Intervention
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project assesses feasibility of providing medically vulnerable rural patients with Medical-Self-Assessment-Boxes containing equipment to use at home during telephone and video consultations (telemedicine) with GPs and other healthcare professionals. COVID-19 has caused an upsurge in primary care telemedicine which the investigators believe can be sustained and optimized to make things better for medically vulnerable rural patients beyond the pandemic. The investigators will achieve this by equipping the participants to self-measure and report key clinical measurements (e.g. blood pressure, temperature, oxygen levels) during telemedicine consultations. Before conducting a major evaluation of the Medical-Self-Assessment-Box for medically vulnerable rural patients the investigators must establish three things: First, to show the investigators can issue a Medical-Self-Assessment-Box to medically vulnerable rural patients and enable them to use it properly. Second, to determine that patients can use the Medical-Self-Assessment-Box effectively during telemedicine consultations. Third, to show that it is possible to measure how well the Medical-Self-Assessment-Box is working by counting how often the boxes are being used and whether use is appropriate and helpful. The knowledge gained will provide the investigators with the information needed to develop a funding proposal to evaluate Medical-Self-Assessment-Boxes for medically vulnerable rural patients in the whole of the UK.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| COPD Asthma | — | UNRESOLVED | — |
| Immunosuppression | — | UNRESOLVED | — |
| Inborn Errors of Metabolism | — | UNRESOLVED | — |
| Organ Transplant | — | UNRESOLVED | — |
| Sickle Cell Disease | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants to use during their telemedicine consultations with health care providers. | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Control
- description
- Participants will be receiving their standard medical care.
- type
- ACTIVE_COMPARATOR
- label
- Intervention
- description
- Participants will be receiving the intervention on top of their standard medical care.
- interventionNames
- Device: A sphygmanometer, a digital thermometer, a pulse oximeter and a peak flow meter will be given to participants to use during their telemedicine consultations with health care providers.
Primary outcomes (2)
- measure
- Short questionnaire
- timeFrame
- 6 months (given at the end of every TM consultation)
- description
- The questionnaire will assess use of equipment, perception of how helpful the equipment was for the consultation and the reasons why it was helpful.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria:
* ● Solid organ transplant recipient
* On the COVID-19 shielding list
* People with specific cancers
* People with cancer who had chemotherapy within the last 2 years
* People with lung cancer that have had radical radiotherapy within the last two years
* People with cancer of the blood or bone marrow such as leukaemia, lymphoma or myeloma who are at end stage treatment
* People that have had immunotherapy or other continuing antibody treatments for cancer within the last two years
* People that had other targeted cancer treatment which can affect the immune system, such as protein kinase inhibitors or PARP inhibitors within the last two years
* People who had bone marrow or stem cell transplants in the last 6 months, or who are still taking immunosuppression drugs
* People with severe respiratory conditions including all cystic fibrosis, severe asthma, and severe COPD
* People with rare diseases and inborn errors of metabolism that significantly increase the risk of infections (such as SCID, homozygous sickle cell anaemia)
* People in immunosuppression therapies sufficient to significantly increase risk of infection
Inclusion criteria for GPs:
* A GP working at the pilot study practice and carried out telemedicine consultations with participants
* A GP who can provide informed consent
Exclusion Criteria:
* People whose GP feels they are not able to participate in the research. People unable to consent to participate. Non-English speakers
Exclusion criteria for GPs:
A GP that cannot provide informed consentReferences
Publications (0)
Data not yet available